RSV Vaccines vs. Monoclonal Antibodies

Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPAProfessorUniversity of Florida College of PharmacyJoshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose. Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations.2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies.0.05 CEU/0.5 HrUAN: 0107-0000-25-312-H01-PInitial release date: 11/3/2025Expiration date: 11/3/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram